12 results
8-K
EX-99.1
URGN
UroGen Pharma Ltd.
13 Jun 24
Regulation FD Disclosure
10:51am
Differences Compared t o HG-NMIBC Market Low-Grade IR-NMIBC High-Grade NMIBC Issues: Chronic recurrence; rarely progresses to Issues: Progression … ; Ther Adv Urol. 2012 Feb; 4(1): 13–32; UroGen Market Research.
Posit ioning UGN-102 for Success Low-Grade IR NMIBC Issues: Chronic recurrence; rarely
8-K
EX-99.1
URGN
UroGen Pharma Ltd.
4 Mar 24
Regulation FD Disclosure
7:00am
Intermediate Risk Disease Low-grade IR NMIBC High-grade NMIBC Issue: chronic recurrence; rarely Issue: progression, metastasis & death progresses
8-K
EX-99.1
URGN
UroGen Pharma Ltd.
7 Feb 24
Regulation FD Disclosure
4:15pm
Intermediate Risk Disease High-grade NMIBC Low-grade IR NMIBC Issue: chronic recurrence; rarely Issue: progression, metastasis & death progresses to high-grade
8-K
EX-99.1
URGN
UroGen Pharma Ltd.
4 Aug 21
UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate
8:11am
or repetitive surgeries to treat chronic recurrences,” said Liz Barrett, President and Chief Executive Officer of UroGen. “Jelmyto was the first of our product
8-K
EX-99.1
wxc8 b3w7wdk
11 Jan 21
Regulation FD Disclosure
8:31am
8-K
EX-99.1
aud32 jznlcr
12 Nov 19
UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent
8:06am
8-K
EX-99.2
xcxp7jrx7
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
- Prev
- 1
- Next